Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PARETEUM CorpTEUM · Entity 144276 | Director | February 19, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PARETEUM Corp
Report date February 19, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,949 |
Reported balance
After 2017-02-19 transaction · row 1
1 source rowRow 1 · 2017-02-19 · Purchase · Acquired 275,911 · Balance 451,949 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 567,186 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 225,670 · Balance 567,186 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 804,646 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 237,460 · Balance 804,646 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 439,774 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 364,872 · Balance 439,774 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 826,454 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2018 Filed May 29, 2018 22:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-18-010863 · rdgdoc.xml · derivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,919 Underlying: Common Stock · 10,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as follows: 85,960 shares vested on March 8, 2018 and 85,959 shares will vest on March 8, 2019. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 22:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantEmployee Stock Option · Derivative | 171,919 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-18-013909 · tv488197_4.xml · derivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,919 Underlying: Common Stock · 171,919 shares Expires 2021-12-20 F1 · derivative.exercise_date: As disclosed in the registrants annual report on Form 10-K for the year ended December 31, 2016, on December 20, 2016, the reporting person was granted an option to purchase 171,919 shares of common stock. The option vests in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 85,960 shares vested on March 8, 2018 and 85,959 shares will vest on March 8, 2019. No Form 4 filing was required upon the initial grant of the option because the option was subject to vesting based on conditions that were not tied to the passage of time and continued employment and not tied directly to the market price of the registrant's common stock. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 02:39 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-000677 · tv482656_4.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,583 F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
| February 19, 2017 Filed Feb 24, 2017 12:19 UTC | PARETEUM Corp TEUM · Entity 144276 | PurchaseCommon Stock | 275,911 | $0.11 | $30,350.21 |
DisclosureSEC source: 0001144204-17-010895 · v460271_4.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,949 Read SEC document |
| November 22, 2016 Filed Jan 13, 2017 10:17 UTC | PARETEUM Corp TEUM · Entity 144276 | SaleSeries A Convertible Preferred Stock · Derivative | 6 | $60,000.00 | $360,000.00 |
DisclosureSEC source: 0001144204-17-002096 · v456875_4.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. F1 · derivative.underlying_shares: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. Read SEC document |
| September 30, 2016 Filed Jan 13, 2017 10:17 UTC | PARETEUM Corp TEUM · Entity 144276 | PurchaseSeries A Convertible Preferred Stock · Derivative | 6 | $60,000.00 | $360,000.00 |
DisclosureSEC source: 0001144204-17-002096 · v456875_4.xml · derivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. F1 · derivative.underlying_shares: The Series A Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into shares of common stock, at the holder's election, at all times since issuance and has no expiration date (though the issuer may force the reporting person to convert the Series A Preferred Stock into shares of common stock at any time after September 2, 2017). Each share of Series A Preferred Stock is convertible into 0.04% of the Company's issued and outstanding shares of common stock immediately prior to conversion. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.